Browse the evidence

Once-weekly semaglutide (2.4 mg) significantly improves health-related quality of life and reduces body weight in obese patients with HFpEF.

If you are obese and have HFpEF, ask your doctor about semaglutide (Ozempic/Wegovy). The STEP-HFpEF trial showed that taking 2.4 mg once weekly significantly improved quality of life and reduced body weight by over 13% compared to placebo.

Dual or triple agonists targeting GLP-1, GIP, and/or Glucagon receptors (GCGR) produce superior weight loss compared to selective GLP-1 receptor agonists alone.

Newer obesity medications that target multiple receptors (like GLP-1, GIP, and Glucagon) are more effective for weight loss than older single-target drugs. These include Tirzepatide and Retatrutide, which are approved or in advanced trials for obesity and diabetes.

Rapid weight loss from GLP-1 and dual/triple agonists can lead to significant loss of lean muscle mass, necessitating strategies to preserve muscle.

While GLP-1 and dual/triple agonists are effective for fat loss, they can also cause significant muscle loss. Patients should consider resistance training and discuss muscle-preserving strategies with their healthcare provider.

Lower intertemporal discount rates (higher patience) are associated with the selection of foods with higher nutritional quality, independent of active health consideration.

People who are naturally more patient (low discounters) tend to choose healthier foods. This trait is stable but can be influenced by interventions like episodic future thinking, which asks individuals to imagine detailed future experiences, thereby reducing impulsive choices and promoting healthier diets.

Actively considering health outcomes during food choice leads to longer decision times, increased use of nutrition information, and consideration of healthier product sets, distinguishing it from habitual decision-making.

Healthy choices often require more time and effort than habitual ones. If you find yourself spending more time looking at labels and considering health impacts, this is a sign of active, model-based decision-making that leads to better outcomes. You can facilitate this by using simple visual cues that make health information easy to process, reducing the cognitive load.

Counselor efficiency in providing personalized feedback for technology-based behavioral weight loss interventions increases significantly over the first 9 months, reducing the time required per feedback message from a mean of 53 minutes to 26 minutes, though the absolute time cost (25-30 minutes) remains high.

If you are designing a weight loss program with human coaching, expect the time required to review and respond to participant data to drop significantly after the first 3-6 months as counselors become proficient. However, even with this efficiency gain, the time cost per interaction remains substantial (approx. 25-30 minutes), suggesting that for large-scale programs, hybrid models using automated feedback or peer support may be necessary to maintain cost-effectiveness.

Intermittent diet breaks may reduce psychological disinhibition (loss of control over eating) compared to continuous energy restriction, although this comes at the cost of a longer total intervention duration.

If you struggle with losing control over your eating (disinhibition) while dieting, scheduled diet breaks might help you stay more in control psychologically than continuous dieting. However, this strategy requires 8 weeks to achieve what continuous dieting does in 6 weeks, so you must be willing to extend your total dieting time.

Set-volume equated hip thrust and back squat training produce similar gluteus maximus hypertrophy, despite hip thrusts eliciting greater acute muscle activation (sEMG).

If your goal is glute growth, you don't need to choose between squats and hip thrusts based on 'activation.' Both exercises produce similar glute growth when you perform the same number of sets and reps to failure. Squats may be better for overall leg development (quads/adductors), while hip thrusts might be preferred for those with back pain or specific mobility issues. Focus on progressive overload and volume equivalence rather than chasing 'burn' or activation feelings.

The Edmonton Obesity Staging System (EOSS) provides a more comprehensive clinical management framework than BMI alone by categorizing obesity based on health complications.

Ask your doctor to use the Edmonton Obesity Staging System (EOSS) to evaluate your health. This focuses on your specific complications rather than just your weight.

Next-generation incretin-based therapies (GLP-1 RAs like semaglutide and dual GLP-1/GIP agonists like tirzepatide) significantly reduce blood pressure and improve cardiovascular outcomes in patients with hypertension, obesity, or type 2 diabetes, acting through both weight loss and direct tissue effects on the cardiovascular system.

If you have high blood pressure, obesity, or type 2 diabetes, ask your doctor about GLP-1 or GLP-1/GIP medications like semaglutide or tirzepatide. These weekly injections not only help with weight loss but also directly lower blood pressure and protect your heart, often allowing you to reduce or stop other blood pressure medications. The benefits extend beyond weight loss through direct effects on your blood vessels and nervous system.

Testosterone therapy preserves lean mass and reduces fat mass when used as an adjunct to incretin-based weight loss medications, potentially counteracting sarcopenia.

Current evidence does not yet support using testosterone to offset muscle loss from GLP-1 weight loss drugs. Resistance exercise and adequate protein intake are the recommended strategies to preserve muscle mass during weight loss.

Individuals with muscle-specific insulin resistance (Impaired Glucose Tolerance, IGT) achieve greater metabolic improvements on a low-fat, high-fiber diet, whereas those with liver-specific insulin resistance (Impaired Fasting Glucose, IFG) respond better to a monounsaturated fat-enriched diet.

If you have insulin resistance, your specific metabolic defect determines which diet works best. If your blood sugar spikes after meals (Impaired Glucose Tolerance, often linked to muscle insulin resistance), a low-fat, high-fiber diet is likely superior. If your fasting blood sugar is high (Impaired Fasting Glucose, linked to liver insulin resistance), a diet emphasizing monounsaturated fats may be more effective. Standard generic diets often fail because they ignore this distinction.

Time-restricted feeding (TRF) and alternative-day fasting (ADF) reduce body weight and improve lipid profiles in NAFLD patients, but TRF offers no additional benefit over daily caloric restriction regarding intrahepatic triglyceride reduction when caloric deficit is matched.

If you have fatty liver, losing weight is the most effective treatment. Time-restricted feeding (eating only between 8am and 4pm) can help you lose weight, but it does not reduce liver fat more than simply counting calories and eating less throughout the day. Choose the method that you can sustain long-term.

High-fibre interventions (e.g., high-fibre bread, whole grains) reduce NAFLD grade and liver enzymes (ALT, AST) independently of weight loss.

If you have fatty liver, increasing your fibre intake through whole grains or high-fibre bread can improve your liver enzymes and disease grade, even if you don't lose weight. This is a simple, sustainable dietary change that directly benefits liver health.

Semaglutide promotes resolution of non-alcoholic steatohepatitis (NASH) without worsening liver fibrosis in patients with NASH and liver fibrosis.

If you have NASH, ask your doctor about Semaglutide. In clinical trials, the highest dose (0.4 mg daily) helped nearly 60% of patients resolve their liver disease without making scarring worse. It is a promising treatment for liver health.

Obesity is an independent risk factor for severe COVID-19 outcomes, including hospitalization, ICU admission, and mortality, with risk increasing as BMI increases.

Obesity significantly increases your risk of severe illness, hospitalization, and death from COVID-19. Maintaining a healthy weight is a critical protective factor against severe viral infections.

Genetically modeled GLP-1 and GIP receptor agonism reduces the risk of Non-Alcoholic Fatty Liver Disease (NAFLD) and lowers ALT levels.

Genetic evidence suggests that activating GLP-1 and GIP receptors improves liver health by reducing the risk of NAFLD and lowering ALT levels. This benefit is independent of alcohol consumption, suggesting a direct metabolic effect on the liver.

Twelve weeks of high-intensity resistance training (70-80% 1RM) significantly improves isokinetic muscle function (peak torque and total work) and hemorheological properties (erythrocyte deformability and aggregation) in middle-aged obese women, despite failing to produce significant changes in body composition, muscle hypertrophy (cross-sectional area), or blood lipid levels.

For middle-aged obese women, a 12-week resistance training program (3 days/week, 70-80% 1RM) will significantly improve muscle strength and blood flow properties (hemorheology) without necessarily changing body weight, muscle size, or blood lipids. Do not stop training if the scale or blood lipid panels don't change immediately; the functional benefits are real and significant. Focus on the feeling of strength and health markers beyond just weight.

Weight gain after a type 2 diabetes diagnosis is associated with an increased risk of cardiovascular disease events and all-cause mortality.

Avoiding weight gain after a type 2 diabetes diagnosis is important for reducing the risk of heart disease and death. Maintaining a stable weight is associated with better cardiovascular outcomes than gaining weight.

General obesity (BMI ≥ 30 kg/m²) significantly increases the risk of cardiovascular and all-cause mortality across all glucose tolerance statuses (normoglycemia, pre-diabetes, and type 2 diabetes), regardless of glycemic control.

Maintaining a healthy weight is crucial for longevity, regardless of whether you have diabetes, pre-diabetes, or normal blood sugar. Obesity significantly raises your risk of dying from heart disease or other causes, so weight management should be a primary health goal.

Central adiposity (high waist circumference) is a significant independent risk factor for incident cardiovascular disease and all-cause mortality in individuals with normal glucose tolerance (NGT).

If you have normal blood sugar, don't ignore your waist size. High waist circumference significantly increases your risk of heart disease and death, even if your glucose levels are normal. Focus on reducing waist circumference through diet and exercise.

High intake of saturated fatty acids (SFA) from modern domesticated animal products and dairy increases LDL cholesterol and cardiovascular disease risk compared to ancestral diets rich in unsaturated fatty acids.

Prioritize unsaturated fatty acids (especially omega-3s) and fiber-rich foods over high-fat dairy and fatty cuts of domesticated meat. This shift aligns your diet with evolutionary norms and helps lower LDL cholesterol, reducing cardiovascular risk.

High intake of saturated fatty acids from modern diets is linked to endotoxemia and inflammation, whereas unsaturated fatty acids do not produce this response.

Be aware that high-fat meals, particularly those high in saturated fat, can trigger an inflammatory response (endotoxemia). Choosing unsaturated fats helps avoid this inflammatory spike.

High consumption of refined cereal grains (white rice/refined wheat) significantly increases the risk of type 2 diabetes in Asian Indians by elevating dietary glycemic load and contributing to visceral obesity.

Reduce your intake of polished white rice and refined wheat. These foods make up half your calories and spike your blood sugar, driving diabetes risk. Swap them for whole grains, millets, or high-fiber rice varieties to lower your glycemic load without abandoning your staple foods.